Tom 3, Supl. D (2023)
Opis przypadku
Opublikowany online: 2024-02-16
Wyświetlenia strony 30
Wyświetlenia/pobrania artykułu 1
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Skuteczne leczenie asciminibem chorego na przewlekłą białaczkę szpikową w fazie przewlekłej w szóstej linii leczenia

Elżbieta Patkowska1, Sebastian Szmit2
DOI: 10.5603/hemedu.98593

Streszczenie

Rozwój terapii celowanych w przewlekłej białaczce szpikowej (CML), w tym inhibitorów kinaz tyrozynowych (TKI) BCR/ABL1 trzech generacji oraz inhibitora STAMP, stanowił przełom w leczeniu chorych, umożliwiając poprawę wyników leczenia i wydłużenie czasu przeżycia chorych. Pozostał jednak problem leczenia chorych z niepowodzeniem lub nietolerancją leczenia TKI, szczególnie w trzeciej, czwartej i kolejnych liniach leczenia CML. W pracy przedstawiono przypadek 61-letniego chorego na CML w fazie przewlekłej leczonego asciminibem w szóstej linii leczenia. Po niepowodzeniu/nietolerancji leczenia imatynibem, dazatynibem, bosutynibem, nilotynibem i ponatynibem chory w trakcie leczenia asciminibem osiągnął odpowiedź na leczenie — całkowitą remisję cytogenetyczną oraz większą odpowiedź molekularną.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009; 114(20): 4361–4368.
  2. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023; 98(4): 658–665.
  3. Réa D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol. 2022; 171: 103580.
  4. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019; 381(24): 2315–2326.
  5. Mauro MJ, Hughes TP, Kim DW, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023; 37(5): 1048–1059.
  6. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021; 138(21): 2031–2041.
  7. Hochhaus A, Réa D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023; 37(3): 617–626.
  8. Kockerols CCB, Janssen JJ, Blijlevens NMA, et al. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population. Haematologica. 2023; 108(1): 240–244.
  9. Chee LCY, Lee N, Grigg A, et al. Clinical outcomes of chronic myeloid leukaemia (CML) patients on asciminib through the managed access program (MAP) in australia. Blood. 2022; 140(Suppl 1): 6800–6802.
  10. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
  11. Sacha T, Wącław J. Postępy w leczeniu chorych na przewlekłą białaczkę szpikową. Hematologia. 2015; 6(1): 63–69.
  12. Hanfstein B, Müller MC, Hehlmann R, et al. SAKK, German CML Study Group. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26(9): 2096–2102.
  13. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3): 232–238.
  14. Lauseker M, Hehlmann R, Hochhaus A, et al. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023; 37(11): 2231–2236.
  15. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872–884.
  16. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22(6): 1200–1206.
  17. Kantarjian H, Pasquini R, Lévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009; 115(18): 4136–4147.
  18. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117(4): 1141–1145.
  19. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007; 117(9): 2562–2569.
  20. Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019; 12(1): 39.
  21. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12(8): 908–916.
  22. Hasinoff BB, Patel D, Wu X. The myocyte-damaging effects of the BCR-ABL1-targeted tyrosine kinase inhibitors increase with potency and decrease with specificity. Cardiovasc Toxicol. 2017; 17(3): 297–306.
  23. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009; 48(7): 964–970.
  24. Giles FJ, Rea D, Rosti G, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017; 143(8): 1585–1596.
  25. Wang Z, Jiang L, Yan H, et al. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Rev Clin Pharmacol. 2021; 14(4): 445–456.
  26. Huang CE, Lee KD, Chang JJ, et al. Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: a national populationbased cohort study. Oncologist. 2023 [Epub ahead of print].
  27. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(2): 440–453.
  28. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20): 2333–2340.
  29. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021; 138(21): 2042–2050.
  30. Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020; 4(3): 530–538.
  31. Jabbour EJ, Deininger M, Abruzzese E, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and optic trials. Blood. 2021; 138(Suppl 1): 2550–2550.
  32. Pasvolsky O, Leader A, Iakobishvili Z, et al. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardiooncology. 2015; 1(1): 5.
  33. Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016; 2(5): 625–632.
  34. Dahlén T, Edgren G, Lambe M, et al. Swedish CML Group and the Swedish CML Register Group. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016; 165(3): 161–166.
  35. Mauro M, Minami Y, Hochhaus A, et al. Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ascembl, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (tkis): an end of study treatment (EOS tx) update, including results from switch population. Blood. 2023; 142(Supplement 1): 4536–4536.
  36. Cirmi S, El Abd A, Letinier L, et al. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). Cancers (Basel). 2020; 12(4).
  37. Cortes JE, Jean Khoury H, Kantarjian H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016; 91(6): 606–616.
  38. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020; 17(8): 503–522.
  39. Herrmann J, Yang EH, Iliescu C, et al. Vascular toxicities of cancer therapies. Circulation. 2016; 133(13): 1272–1289.
  40. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013; 27(6): 1310–1315.
  41. Caocci G, Mulas O, Abruzzese E, et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol. 2019; 37(3): 296–302.
  42. Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev. 2018; 32(4): 289–299.
  43. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.